Synthetic steriod (R2323) as a once-a-week oral contraceptive

S. S. David, G. R. Huggins, C. R. Garcia, C. Busacca

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Five milligrams of the steroid R2323 (13-β-ethyl-17 α-ethynyl-17hydroxygona-4,9,11-trien-3-one (R2323) were administered orally once weekly to 28 subjects for a total of 138 treatment cycles. No pregnancies occurred. The predominant side effects were irregular vaginal bleeding, headache, weight gain, and acne. Administration of the drug was stopped by the investigator in 4 patients (14%) because of the onset of headaches. Four patients discontinued the drug for other reasons. In 8 of 26 subjects (31%), endometrial biosy in the third treatment cycle showed secretory endometrium. This suggests a variable central suppression with the 5-mg dose schedule. Patients were enthusiastic about the once-weekly oral administration. This contraceptive may be useful in a select group of women.

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalFertility and sterility
Issue number3
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Synthetic steriod (R2323) as a once-a-week oral contraceptive'. Together they form a unique fingerprint.

Cite this